Adoptive immunotherapy of HCMV infection

References

• Boeckh M, Bowden RA, Gooley T, et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781–2
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Hebart H, et al. (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–20
   PubMed Web of Science ®Google Scholar
• Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14: 831–5
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757–63
   PubMed Web of Science ®Google Scholar
• Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111–16
   PubMed Web of Science ®Google Scholar
• Reusser P, Riddell SR, Meyers JD, et al. Cytotoxic T lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373–80
   PubMed Web of Science ®Google Scholar
• Ljungman P, Lonnqvist B, Wahren B, et al. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients: a one-year follow-up. Transplantation 1985; 40: 515–20
   Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038–44
   PubMed Web of Science ®Google Scholar
• Limaye AP, Bowden RA, Myerson D, Boeckh M. Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis 1997; 24: 830–35
   Google Scholar
• Couriel D, Canosa J, Engler H, et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18: 347–53
   PubMedGoogle Scholar
• Hebart H, Brugger W, Grigoleit U, et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183–85
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78–83
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Kruger W, et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donor using pretransplant in vivo T-cell depletion with anti-thymocyte globuline. Br J Haematol 2001; 113: 1060–71
   PubMed Web of Science ®Google Scholar
• Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255–60
   PubMed Web of Science ®Google Scholar
• Junghans C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–85
   Google Scholar
• Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358–64
   PubMed Web of Science ®Google Scholar
• Apperley JF, Goldman JM. Cytomegalovirus: biology, clinical features and methods for diagnosis. Bone Marrow Transplant 1988; 3: 253–64
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543–58
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407–14
   PubMed Web of Science ®Google Scholar
• Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65: 432–6
   PubMedGoogle Scholar
• Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373–80
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094–7
   PubMed Web of Science ®Google Scholar
• Junghans C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–85
   Google Scholar
• Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–9
   PubMed Web of Science ®Google Scholar
• Ganepola S, Gentilini C, Hilbers U, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 293–9
   PubMed Web of Science ®Google Scholar
• Boland G, Vlieger A, Ververs C, De Gast G. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin Exp Immunol 1992; 88: 506–11
   Google Scholar
• Mendes AV, Benard G, Pereira CB, et al. Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-γ production in allogeneic and autologous bone marrow transplantation. Acta Haematol 2002; 107: 187–94
   Google Scholar
• Couriel D, Canosa J, Engler H, et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18: 347–53
   PubMedGoogle Scholar
• Podlech J, Holtappels R, Wirtz N, et al. Reconstitution of CD8T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol 1998; 79: 2099–104
   PubMedGoogle Scholar
• Einsele H, Bertz H, Beyer J, et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82: 175–85
   Google Scholar
• Einsele H, Ehninger G, Hebart H, et al. PCR monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy. Blood 1995; 86: 2815–20
   PubMed Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992; 257: 238–41
   PubMed Web of Science ®Google Scholar
• Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001; 98: 505–12
   PubMed Web of Science ®Google Scholar
• Koehne G, Gallardo HF, Sadelain M, et al. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 2000; 96: 109–17
   Google Scholar
• Kondo E, Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002; 169: 2164–71
   PubMed Web of Science ®Google Scholar
• Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T-cells by peptide-pulsed dendritic cells. Br J Haematol 2001; 113: 231–9
   Google Scholar
• Vannucchi AM, Glinz S, Bosi A, et al. Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide. Br J Haematol 2001; 113: 479–82
   Google Scholar
• Peggs KS, Preiser W, Kottaridis PD, et al. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001; 97: 994–1000
   PubMed Web of Science ®Google Scholar
• Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002; 185: 1709–16
   PubMed Web of Science ®Google Scholar
• Waldrop SL, Pitcher CJ, Peterson DM, et al. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99: 1739–50
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T-cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–22
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375–7
   PubMed Web of Science ®Google Scholar
• McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994; 43: 103–10
   PubMed Web of Science ®Google Scholar
• Toro AI, Ossa J. PCR activity of CMV in healthy CMV-seropositive individuals: does latency need redefinition?. Res Virol 1996; 147: 233–8
   Google Scholar
• Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994; 343: 268–9
   PubMedGoogle Scholar
• Khan N, Cobbold M, Keenan R, et al. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 2002; 185: 1025–34
   Google Scholar
• Hebart H, Rauser G, Stevanovic S, et al. A CTL epitope from HCMV IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic SCT. Exp Hematol 2003; 31: 966–73
   Google Scholar
• Koehne G, Smith KM, Ferguson TL, et al. Quantitation, selection, and functional characterization of Epstein–Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002; 99: 1730–40
   PubMed Web of Science ®Google Scholar
• Gilbert MJ, Riddell SR, Plachter B, et al. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996; 383: 720–2
   PubMed Web of Science ®Google Scholar
• Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002; 99: 3830–7
   PubMed Web of Science ®Google Scholar
• Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002; 2: 831–44
   PubMed Web of Science ®Google Scholar
• Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+ T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226–40
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673–85
   PubMed Web of Science ®Google Scholar
• Jonjic S, Mutter W, Weiland F, et al. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med 1989; 169: 1199–212
   PubMed Web of Science ®Google Scholar
• Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545–86
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101: 2686–92
   PubMed Web of Science ®Google Scholar
• Davignon JL, Castanie P, Yorke JA, et al. Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol 1996; 70: 2162–9
   PubMed Web of Science ®Google Scholar
• Casazza JP, Betts MR, Price DA, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865–77
   PubMed Web of Science ®Google Scholar
• Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94–6
   PubMed Web of Science ®Google Scholar
• Keenan RD, Ainsworth J, Khan N, et al. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 2001; 115: 428–34
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379–86
   PubMed Web of Science ®Google Scholar
• Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031–6
   PubMed Web of Science ®Google Scholar
• Knabel M, Franz TJ, Schiemann M, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8: 631–7
   PubMed Web of Science ®Google Scholar
• Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999; 93: 1506–10
   PubMed Web of Science ®Google Scholar
• Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565–72
   PubMed Web of Science ®Google Scholar
• Matsui K, Boniface JJ, Reay PA, et al. Low affinity interaction of peptide–MHC complexes with T cell receptors. Science 1991; 254: 1788–91
   PubMed Web of Science ®Google Scholar
• Engstrand M, Tournay C, Peyrat MA, et al. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000; 69: 2243–50
   PubMed Web of Science ®Google Scholar
• Singhal S, Shaw JC, Ainsworth J, et al. Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. Transplantation 2000; 69: 2251–9
   PubMed Web of Science ®Google Scholar
• Jin X, Demoitie MA, Donahoe SM, et al. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J Infect Dis 2000; 181: 165–75
   Google Scholar
• Gillespie GM, Wills MR, Appay V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74: 8140–50
   PubMed Web of Science ®Google Scholar
• Marchant A, Appay V, Van Der Sande M, et al. Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest 2003; 111: 1747–55
   PubMed Web of Science ®Google Scholar
• Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52: 165–73
   Google Scholar
• Dal Porto J, Johansen TE, Catipovic B, et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA 1993; 90: 6671–5
   PubMed Web of Science ®Google Scholar
• O'Herrin SM, Lebowitz MS, Bieler JG, et al. Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors. J Exp Med 1997; 186: 1333–45
   PubMedGoogle Scholar
• Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31–7
   PubMed Web of Science ®Google Scholar
• Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998; 4: 975–8
   PubMed Web of Science ®Google Scholar
• Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30: 1676–82
   PubMed Web of Science ®Google Scholar
• Vaz-Santiago J, Lule J, Rohrlich P, et al. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 2001; 75: 7840–7
   Google Scholar
• Nylander S, Kalies I. Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry. J Immunol Methods 1999; 224: 69–76
   Google Scholar
• Simon MM, Hausmann M, Tran T, et al. In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A×B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med 1997; 186: 1781–6
   PubMed Web of Science ®Google Scholar
• Trapani JA. Granzymes: a family of lymphocyte granule serine proteases. Genome Biol 2001; 2: 3014.1–3014.7
   Google Scholar
• Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65–78
   PubMed Web of Science ®Google Scholar
• Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 1999; 11: 183–90
   PubMedGoogle Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–4
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397–406
   PubMed Web of Science ®Google Scholar
• Hebart H, Einsele H. Diagnosis and treatment of cytomegalovirus infection. Curr Opin Hematol 1998; 5: 483–7
   Google Scholar
• Wang Z, La Rosa C, Mekhoubad S, et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 2004; 104: 847–56
   PubMed Web of Science ®Google Scholar
• Grigoleit, GU, Kapp, M, Hebart, H, , et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of HCMV-specific CTL responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 2007; 196:699–704.
   PubMed Web of Science ®Google Scholar